IBRUTINIB-INDUCED CHRONIC DEMYELINATING POLYNEUROPATHY IN A 65-YEAR-OLD MAN WITH CHRONIC LYMPHOID LEUCOSIS: A CLINICAL CASE
Relevance. Most of oncological patients undergo chemotherapy, which has a wide range of various toxic reactions including polyneuropathy. Ibrutinib is a relatively new medicine with a few side effects associated with peripheral polyneuropathy. Demyelinating polyneuropathy induced by this drug is not...
Main Authors: | N.A. Suponeva, D.A. Grishina, M.A. Piradov |
---|---|
Format: | Article |
Language: | English |
Published: |
Amaltea Medical Publishing House
2018-03-01
|
Series: | Romanian Journal of Neurology |
Subjects: | |
Online Access: | http://revistemedicale.amaltea.ro/Romanian_Journal_of_NEUROLOGY/Revista_Romana_de_NEUROLOGIE-2018-Nr.1/RJN_2018_1_Art-08.pdf |
Similar Items
-
Clinical heterogeneity of chronic inflammatory demyelinating polyneuropathy: diagnostic challenges
by: A. S. Rizvanova, et al.
Published: (2020-03-01) -
Atypical Chronic Inflammatory Demyelinating Polyneuropathy
by: J Gordon Millichap
Published: (2010-11-01) -
Fatigue in patients with chronic inflammatory demyelinating polyneuropathy
by: R. A. Gapeshin, et al.
Published: (2021-02-01) -
Atypical variants of chronic inflammatory demyelinating polyneuropathy with benign course: a clinical observation for 8 patients without pathogenic therapy
by: D. A. Grishina, et al.
Published: (2020-08-01) -
The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with diabetes mellitus
by: R. A. Gapeshin, et al.
Published: (2020-06-01)